Oragenics Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts...
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassiopea SpA (CPPSF), Oragenics (OGEN) and CytomX
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Topline Data for Phase 2 Trial of AGO13 in Oral Mucositis in Early 2Q20 Oragenics, Inc. (NYSE:OGEN) is currently conduc
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D.,
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of en
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publicatio
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vi
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE